Sunitinib-induced severe hypoglycemia in a diabetic patient

被引：14

作者：

Demirci, Ayse ^{[1
]}

Bal, Oznur ^{[1
]}

Durnali, Ayse ^{[1
]}

Ekinci, Ahmet S. ^{[1
]}

Esbah, Onur ^{[1
]}

Alkis, Necati ^{[1
]}

Oksuzoglu, Berna ^{[1
]}

机构：

[1] Ankara Oncol Educ & Res Hosp, Dept Med Oncol, TR-06200 Ankara, Turkey

来源：

JOURNAL OF ONCOLOGY PHARMACY PRACTICE | 2014年 / 20卷 / 06期

关键词：

diabetes; hypoglycemia; Sunitinib;

D O I：

10.1177/1078155213508441

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction:Sunitinib is an oral inhibitor of tyrosine kinase that was used for the treatment of mRCC. The general side effects are fatigue, asthenia, diarrhea, mucositis, nausea, vomiting, skin changes, hypertension, hypothyroidism and hematologic side effects. In addition, sunitinib-induced hypoglycemia has also been reported. There are limited number of case reports related to sunitinib-induced hypoglycemia. Case presentation:In this case report, we have presented a patient with type 2 diabetes mellitus (DM) with emerging severe hypoglycemia after sunitinib treatment. It was shown that blood glucose levels were normalized two weeks after the interruption of sunitinib. Conclusion:Although the underlying mechanism of sunitinib-induced hypoglycemia is not completely understood, sunitinib can be regarded to have an antidiabetic effect. In the literature, there are some reports about sunitinib/other TKI induced hypoglycemia; however, life threatening hypoglycemia is rare. There is no case report of severe hypoglycemia due to imatinib; however, there are two case reports with severe hypoglycemia due to sunitinib treatment. Symptomatic hypoglycemic episodes due to sunitinib may lead to hospital admission. Diabetic patients may develop severe hypoglycaemia and it should be kept in mind that the discontinuation of antihyperglycemic treatment may be required. Therefore, blood glucose levels should be closely monitored in diabetic patients with mRCC during sunitinib therapy.

引用

页码：469 / 472

页数：4

共 13 条

[1] Faivre S., Demetri G., Sargent W., Molecular basis for sunitinib efficacy and future clinical development, Nat Rev Drug Discov, 6, pp. 734-745, (2007)
[2] Schmidinger M., Arnold D., Szczylik C., Optimizing the use of sunitinib in metastatic renal cell carcinoma: An update from clinical practice, Cancer Invest, 28, pp. 856-864, (2010)
[3] Motzer R.J., Hutson T.E., Tomczak P., Sunitinib vs interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 2, pp. 115-124, (2007)
[4] Motzer R.J., Rini B.I., Bukowski R.M., Sunitinib in patients with metastatic renal cell carcinoma, JAMA, 21, pp. 2516-2524, (2006)
[5] Templeton A., Brandle M., Cerny T., Remission of diabetes while on sunitinib treatment for renal cell carcinoma, Ann Oncol, 4, pp. 824-825, (2008)
[6] Kamba T., Tam B.Y., Hashizume H., VEGF-dependant plasticity of fenestrated capillaries in the normal adult microvasculature, Am J Physiol Heart Circ Physiol, 290, pp. H560-H576, (2006)
[7] Hagerkvist R., Sandler S., Mokhtari D., Amelioration of diabetes by imatinib mesylate (Gleevec): Role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning, FASEB J, 21, pp. 618-628, (2007)
[8] Veneri D., Franchini M., Bonora E., Imatinib and regression of type 2 diabetes, N Engl J Med, 10, pp. 1049-1050, (2005)
[9] Billemont B., Medioni J., Taillade L., Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib, Br J Cancer, 99, pp. 1380-1382, (2008)
[10] Lee Y., Jung H.S., Choi H.J., Life-threatening hypoglycemia induced by a tyrosine kinase inhibitor in a patient with neuroendocrine tumor: A case report, Diabetes Res Clin Pract, 93, pp. e68-e70, (2011)

← 1 2 →